The management of primary central nervous system lymphoma related to AIDS in the HAART era

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 648-653

  González Aguilar, Alberto ^a   Soto Hernández, José Luis ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

acquired immunodeficiency disease syndrome; AIDS; AIDS PCNSL; central nervous system; highly active antiretroviral therapy; non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOMODULATION; INCIDENCE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WHOLE BRAIN RADIOTHERAPY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, AIDS-RELATED;

EID: 80054098709     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834b6adc     Document Type: Review

References (68)

1. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 2007; 60:1397-1402. (Pubitemid 350247257)
2. Haldorsen IS, Krakenes J, Goplen AK, et al. AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer 2008; 8:225.
3. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of tumours. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. WHO press: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp. 236-237.
4. Singer EJ, Valdes-Sueiras M, Commins D, et al. Neurologic presentations of AIDS. Neurol Clin 2010; 28:253-275.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician-gls/f-guidelines. asp. ([Accessed 2 March 2011]
6. Dhir AA, Sawant SP. Malignancies in HIV: the Indian scenario. Curr Opin Oncol 2008; 20:517-521.
7. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. Acquir Immune Defic Syndr 2009; 52:611-622.
8. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14:1065-1074.
9. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 2008; 49 (Suppl 1):43-51.
10. Kreisl TN, Panageas KS, Elkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49:1710-1716.
11. Cá ceres W, Cruz-Amy M, Díaz-Melé ndez V. AIDS-related malignancies: revisited. P R Health Sci J 2010; 29:70-75.
12. Kitai R, Matsuda K, Adachi E, et al. Epstein-Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir (Tokyo) 2010; 50:114-118.
13. Schulz T. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125:1755-1763.
14. Zhang Y, Peng J, Tang Y, et al. The prevalence of Epstein-Barr virus infection in different types and sites of lymphomas. Jpn J Infect Dis 2010; 63:132-135.
15. Zoufaly A, Stellbrink H, Heiden M, et al. Cumulative HIV viremia during highly active retroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79-87.
16. Ramos da Silva S, Elgui de Oliveira D. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett 2011; 305:175-185.
17. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328-1337. (Pubitemid 38375368)
18. Pagè s F, Galon J, Karaschuk G, et al. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood 2005; 105:1632-1639.
19. Piriou E, van Dort K, Nanlohy NM, et al. Loss of EBNA1-specific memory CD4\+ and CD8\+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005; 106:3166-3174. (Pubitemid 41565915)
20. Kunishio K, Nagao S. Prognostic implication of p27 expression in primary central nervous system lymphoma. Brain Tumor Pathol 2006; 23:77-81. (Pubitemid 44607273)
21. Gloghini A, Gaidano G, Larocca LM, et al. Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1. Am J Pathol 2002; 161:163-171. (Pubitemid 34760782)
22. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004; 100:2627-2636. (Pubitemid 38715769)
23. Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011; 101:257-265.
24. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17:554-560. (Pubitemid 29075242)
25. Corti M, Metta H, Villafañe MF, et al. Stereotactic brain biopsy in the diagnosis of focal brain lesions in AIDS. 2008; 68:285-290.
26. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42:433-436.
27. Senocak E, Oguz KK, Ozgen B, et al. Imaging features of CNS involvement in AIDS. Diagn Interv Radiol 2010; 16:193-200.
28. Haque S, Law M, Abrey LE, Young RJ. Imaging of lymphoma of the central nervous system, spine, and orbit. Radiol Clin North Am 2008; 46:339-361; ix. (Pubitemid 351932047)
29. Chaudhari VV, Yim CM, Hathout, et al. Atypical imaging appearance of toxoplasmosis in an HIV patient as a butterfly lesion. J Magn Reson Imaging 2009; 30:873-875.
30. Wilson AJ, Sayer RA, Edwards SG, et al. A comparison of computed tomography and magnetic resonance brain imaging in HIV-positive patients with neurological symptoms. Int J STD AIDS 2010; 21:198-201.
31. Cotton F, Ongolo-Zogo P, Louis-Tisserand G, et al. Diffusion and perfusion MR imaging in cerebral lymphomas. J Neuroradiol 2006; 33:220-228. (Pubitemid 44569071)
32. Zacharia TT, Law M, Naidich TP, et al. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008; 18:411-417.
33. Taillibert S, Guillevin R, Menuel C, et al. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol 2008; 86:225-229. (Pubitemid 350263422)
34. Kita T, Hayashi K, Yamamoto M, et al. Does supplementation of contrast MR imaging with thallium-201 brain SPECT improves differentiation between benign and malignant ring-like contrast-enhanced cerebral lesions? Ann Nucl Med 2007; 21:251-256. (Pubitemid 350104526)
35. Akter M, Hirai T, Makino K, et al. Diffusion-weighted imaging of primary brain lymphomas: effect of ADC value and signal intensity of T2-weighted imaging. Comput Med Imaging Graph 2008; 32:539-543.
36. Warwick JM, Sathekge MM. PET/CT scanning with a high HIV/AIDS prevalence. Transfus Apher Sci 2011; 44:167-172.
37. Young RJ, Ghesani MV, Kagetsu NJ, et al. Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients. AJNR Am J Neuroradiol 2005; 26:1973-1979.
38. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6:818-820; 840.
39. Karantanis D, O'eill BP, Subramaniam RM, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007; 28:834-841. (Pubitemid 47494107)
40. Kawai N, Okubo S, Miyake K, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 2010; 24:335-343.
41. Smego RA Jr, Orlovic D, Wadula J. An algorithmic approach to intracranial mass lesions in HIV/AIDS. Int J STD AIDS 2006; 17:271-276.
42. Rosenow JM, Hirschfeld A. Utility of brain biopsy in patients with acquired immunodeficiency syndrome before and after introduction of highly active antiretroviral therapy. Neurosurgery 2007; 61:130-140. (Pubitemid 47356484)
43. Formenti SC, Gill PS, Lean E, et al. Primary central nervous system lymphoma in AIDS. Results of radiation therapy. Cancer 1989; 63:1101-1107. (Pubitemid 19074739)
44. Donahue BR, Sullivan JW, Cooper JS. Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma. Cancer 1995; 76:328-332.
45. Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73:206-211. (Pubitemid 20238500)
46. Goldstein JD, Dickson DW, Moser FG, et al. Primary central nervous system lymphoma in acquired immune deficiency syndrome. A clinical and pathologic study with results of treatment with radiation. Cancer 1991; 67:2756-2765.
47. Khoo VS, Wilson PC, Sexton MJ, et al. Acquired immunodeficiency syndromerelated primary cerebral lymphoma: response to irradiation. Australas Radiol 2000; 44:178-184. (Pubitemid 30337669)
48. Hoffmann C, Tabrizian S, Wolf E. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAARTinduced immune recovery. AIDS 2001; 15:2119-2127. (Pubitemid 33101819)
49. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17:1787-1793. (Pubitemid 37000096)
50. Nagai H, Odawara T, Ajisawa A, et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 2010; 84:499-505.
51. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25:691-700.
52. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994; 44:1473-1479. (Pubitemid 24247440)
53. Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11:1725-1730. (Pubitemid 27470274)
54. Chamberlain MC, Kormanik PA. AIDS-related central nervous system lymphomas. J Neurooncol 1999; 43:269-276. (Pubitemid 29488385)
55. Ambinder RF, Lee S, Curran WJ, et al. Phase II intergroup trial of sequential chemotherapy and radiotherapy for AIDS-related primary central nervous system lymphoma. Cancer Therapy 2003; 1:215-221.
56. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89:1100-1108. (Pubitemid 39295481)
57. Bossolasco S, Falk KI, Ponzoni M, et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis 2006; 42:e21-e25.
58. Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999; 15:713-719. (Pubitemid 29237394)
59. Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis 2002; 34:1660-1662. (Pubitemid 34615457)
60. Slobod KS, Taylor GH, Sandlund JT, et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356:1493-1494.
61. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
62. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153. (Pubitemid 47233717)
63. Miralles P, Berenguer J, Ribera JM, et al. Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr 2007; 44:167-173. (Pubitemid 46292219)
64. Dal Maso L, Polesel J, Serraino D, et al. Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100:840-847.
65. Lockey TD, Zhan X, Surman S, et al. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front Biosci 2008; 13:5916-5927.
66. McGowan JP, Shah S. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 1998; 12:952-954. (Pubitemid 28241411)
67. Corales R, Taege A, Rehm S, et al. Regression of AIDS related CNS lymphoma with HAART. In: Proceedings of the XIII International AIDS Conference; Durban; July 2000; abstract MoPpB1086.
68. Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 2007; 21:900-907.